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Over the last decade, a growing body of epi-
demiologic and clinical evidence has raised the
possibility of the potentially deleterious effects
of ambient pollutant particles on cardiovascular
health. Exposure to particulate matter (PM) has
consistently been associated with increased hos-
pitalization and mortality due to cardiovascular
diseases (Pope et al. 2004). It has been esti-
mated that for each 10-µg/m3 increase in PM10
(PM < 10 µm in aerodynamic diameter), the
daily cardiopulmonary mortality increased by
0.3% (Dominici et al. 2003). The risk is espe-
cially high in patients with congestive heart fail-
ure, frequent arrhythmias, or both (Goldberg
et al. 2001; Mann et al. 2002), and the cata-
strophic cardiac events may occur as early as
hours after PM exposure (Peters et al. 2001).
The mechanisms for the acute increase in
cardiovascular events are not entirely clear.
Several hypotheses have been proposed, includ-
ing imbalance in autonomic systems, increases
in procoagulant activities, and systemic release
of inﬂammatory mediators (Brook et al. 2004;
Donaldson et al. 2001).
Recent in vivo and in vitro evidence also
indicate that PM may cause endothelial dys-
function and vasoconstriction. Exposure to
concentrated ambient particles (CAPs;
median, 182.75 µg/m3) for 5 hr/day for
3 days decreased the lumen:wall area ratio of
small pulmonary arteries in rats, indicating
increased pulmonary vascular resistance
(Batalha et al. 2002). Motorcycle exhaust par-
ticulate enhanced constriction of rat aortic
rings induced by phenylephrine (Tzeng et al.
2003). Exposure to PM for 4 weeks increased
atherosclerotic plaque formation in rabbits
(Suwa et al. 2002). Inhalation of CAPs
(~ 150 µg/m3) and ozone (120 ppb) for 2 hr
causes acute constriction of the brachial artery
in healthy adults (Brook et al. 2002). An air
pollution episode in Germany was associated
with increases in systemic blood pressure by
as much as 8 mm Hg (Ibald-Mulli et al.
2001). Various vasoconstrictor mechanisms
have been demonstrated, including the release
of endothelins (Bouthillier et al. 1998;
Thomson et al. 2004), activation of the
epithelial growth factor receptor (EGFR;
Huang et al. 2002), and inhibition of nitric
oxide production (Bai et al. 2001; Bouthillier
et al. 1998; Huang et al. 2002; Ikeda et al.
1995). These mechanisms, however, could
not completely explain the epidemiologic
ﬁndings of the acute effects of PM on cardio-
vascular events, which have a lag time of
hours. The endothelins are potent vaso-
constrictors, but the increased release occurs
24 hr after PM exposure. Vasoconstriction
caused by the activation of EGFR is relatively
weak, and the inhibition of NO production
results in a loss of vasodilator activity.
The circulating and local renin–angiotensin
systems have been known to play a key role in
the pathogenesis of cardiovascular diseases
(Dzau 1988). The end product of this path-
way, angiotensin II, is one of the most potent
vasoconstrictors, and its effects are mediated
primarily by the G protein-coupled angio-
tensin type 1 receptor (AT1R; Daugherty and
Cassis 2004). Agonist binding of AT1R acti-
vates mitogen-activated protein kinases
(MAPKs; Touyz and Schiffrin 2000), a com-
mon early signaling event induced by PM
exposure (Roberts et al. 2003; Silbajoris et al.
2000). In preliminary experiments, we found
that pulmonary vasoconstriction induced by
St. Louis, Missouri, urban particles [UPs;
Standard Reference Material (SRM) 1648]
could be inhibited by losartan, an AT1R
antagonist. In the present study, we charac-
terized the role of AT1R in UP-induced vaso-
constriction and MAPK activation. The study
was performed in the isolated pulmonary
artery ring system and human pulmonary
artery endothelial cells (HPAECs).
Materials and Methods
Reagents and chemicals. We obtained HPAECs
from Cell Applications, Inc. (San Diego, CA).
We purchased endothelial growth medium
(EGM-2) and supplements from Clonetics
(Bio Whittaker Inc., Walkersville, MD), and
vanadyl sulfate (VOSO4) and copper sulfate
(CuSO4) from Johnson Matthey Co. (Ward
Hill, MA). We obtained Captopril from Sigma
Chemical Co. (St. Louis, MO); SB203580, a
p38 MAPK inhibitor, and PD98059 an
ERK1/2 MAPK inhibitor, from Calbiochem-
Novabiochem Corp. (San Diego, CA); and
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Exposure to particulate matter (PM) is associated with acute cardiovascular mortality and morbid-
ity, but the mechanisms are not entirely clear. In this study, we hypothesized that PM may acti-
vate the angiotensin type 1 receptor (AT1R), a G protein-coupled receptor that regulates
inflammation and vascular function. We investigated the acute effects of St. Louis, Missouri,
urban particles (UPs; Standard Reference Material 1648) on the constriction of isolated rat pul-
monary artery rings and the activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2)
and p38 mitogen-activated protein kinases (MAPKs) in human pulmonary artery endothelial cells
with or without losartan, an antagonist of AT1R. UPs at 1–100 µg/mL induced acute vaso-
constriction in pulmonary artery. UPs also produced a time- and dose-dependent increase in phos-
phorylation of ERK1/2 and p38 MAPK. Losartan pretreatment inhibited both the vasoconstriction
and the activation of ERK1/2 and p38. The water-soluble fraction of UPs was sufﬁcient for inducing
ERK1/2 and p38 phosphorylation, which was also losartan inhibitable. Copper and vanadium, two
soluble transition metals contained in UPs, induced pulmonary vasoconstriction and phosphoryla-
tion of ERK1/2 and p38, but only the phosphorylation of p38 was inhibited by losartan. The UP-
induced activation of ERK1/2 and p38 was attenuated by captopril, an angiotensin-converting
enzyme inhibitor. These results indicate that activation of the local renin–angiotensin system may
play an important role in cardiovascular effects induced by PM. Key words: air pollutant,
angiotensin II, angiotensin-converting enzyme, copper, ERK, p38, vanadium. Environ Health
Perspect 113:1009–1014 (2005). doi:10.1289/ehp.7736 available via http://dx.doi.org/ [Online
15 April 2005]
Researchlosartan potassium from Merck & Co., Inc.
(West Point, PA). Monoclonal antibodies
against phospho-p38, total extracellular signal-
regulated kinases 1 and 2 (ERK1/2), total p38,
and phospho-ERK1/2 were purchased from
Cell Signaling Technology, Inc. (Beverly, MA).
Horseradish peroxidase (HRP)-conjugated
goat anti-rabbit and goat anti-mouse IgG were
obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). We purchased molecular
mass standards, polyacrylamide, and buffers
from Bio-Rad (Richmond, CA). The enhanced
chemiluminescent (ECL) blotting detection
reagents were purchased from Amersham
Biosciences Corp. (Piscataway, NJ). 
Urban particles. We purchased St. Louis
UPs (SRM 1648) from the National Institute
of Standards and Technology (Gaithersburg,
MD). They were prepared from urban PM
collected in the St. Louis, Missouri, area in a
baghouse over a period of > 12 months. The
material was removed from the filter bags,
combined in a single lot, screened through a
ﬁne mesh sieve to remove extraneous materials,
and thoroughly blended in a v-blender. The
material was then packaged into sequentially
numbered bottles. The major constituent ele-
ments are (mass fraction) aluminum, 3.4%;
iron, 3.9%; and potassium, 1.1%; the minor
constituent elements are sodium, 0.43%; lead,
0.66%; and zinc, 0.48%. There are also trace
constituents (nanograms per milligram),
including arsenic (115), cadmium (75),
chromium (403), copper (609), manganese
(786), nickel (82), selinium (27), uranium
(5.5), and vanadium (127). UPs were sus-
pended in distilled deionized water for use in
experiments.
Preparation of the water-soluble and
-insoluble fraction of UP. The water suspen-
sion of UPs was centrifuged for 10 min at
14,000 rpm; we then collected the super-
natant and centrifuged it again. We repeated
this procedure several times until no sedi-
ments could be seen in the supernatant. This
ﬁnal supernatant was designated as the water-
soluble fraction of UP. The pellets from the
first centrifuge were washed using deionized
distilled water for three times and then resus-
pended in appropriate volume of water. We
designated this as the water-insoluble fraction
of UP.
Isolated perfused rat pulmonary artery
ring model. We removed segments of the right
and left main pulmonary arteries of Sprague-
Dawley rats (250–350 g) measuring approxi-
mately 2–3 mm and placed them in the
Krebs-Henseleit (KH) buffer as described pre-
viously (Li et al. 2004). The artery segments
were then suspended in the Radnoti four-unit
tissue organ bath system (Glass Technology
Inc., Monrovia, CA). The reservoirs held
Li et al.
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Figure 1. Constriction of isolated rat pulmonary
artery induced by UPs (A) and the effects of losar-
tan, an angiotensin II receptor subtype 1 antagonist,
on UP-induced vasoconstriction (B). The constric-
tion was measured by ring tension and expressed
as percentage of maximum tension induced by 1 µM
phenylephrine. n = 6–8 rings from different animals.
*p < 0.05 compared with 0.01 µg/mL; #p < 0.05 compared
with UP.
Figure 2. Effects of UPs on phosphorylation of p38 and ERK MAPKs. Time-dependent increase in phospho-
ERK1/2 (p-ERK1/2; A) and phospho-p38 (p-p38; B); conﬂuent cells were treated with 10 µg/mL UPs for up to
20 min. Dose-dependent increase in p-ERK1/2 (C) and p-p38 (D); cells were treated with 1, 10, and
100 µg/mL UPs for 10 min. Cell lysates (50 µg) were separated by 10% SDS-PAGE gel and immunoblotted
with monoclonal antibodies against p-p38 or ERK1/2 as described in “Materials and Methods.” Results are
representative of three independent experiments.
Figure 3. Effects of PD98059 (A) and SB203580 (B) on UP-induced phosphorylation of ERK1/2 and p38,
respectively. Quiescent cells were pretreated with PD98059 (30 µM) and SB203580 (10 µM) for 30 min and
then incubated with 10 µg/mL UPs for 10 min; phosphorylation of p38 (p-p38) and ERK (p-ERK1/2) in cell
lysates was measured by Western blotting. Effects of PD98059 (30 µM; C) and SB203580 (10 µM; D) on UP-
induced pulmonary vasoconstriction (C) and (D), respectively. n = 4–6 rings from different animals; results
are representative of three independent experiments. 
*p < 0.05 compared with UP.20 mL KH buffer and were bubbled con-
stantly with 21% O2/5% CO2 gas. After a
10–15 min stabilization period, the baseline
tension of the rings was adjusted to 1 g before
all experiments. We exposed the artery rings to
increasing doses of particles from 1 to
100 µg/mL, and the rings were washed with
buffer between the two doses of particles. We
recorded the maximum tension within 5 min
after each dose of particles.
Cultured HPAECs. HPAECs were grown
in endothelial growth medium (EGM-2) sup-
plemented with 2% fetal bovine serum,
0.04% hydrocortisone, 0.4% human fibro-
blast growth factor-B, 0.1% vascular endothe-
lial growth factor, 0.1% R3-insulin growth
factor-1, 0.1% ascorbic acid, 0.1% human
epithelial growth factor, 0.1% GA-1000, and
0.1% heparin. We used cells at passages 4–9
grown to 80% confluence in six-well plates
for the experiments. The cells were exposed to
particles at 1–100 µg/mL for up to 20 min.
Western blot analysis. After the exposure,
the cells were washed once with ice-cold
phosphate-buffered saline (PBS) and then
lysed with RIPA buffer (1% Nonidet P-40,
0.5% sodium deoxycholate, and 0.1% SDS in
PBS, pH 7.4) containing 0.1 mM VOSO4
and protease inhibitors (0.5 mg/mL aprotinin,
0.5 mg/mL E-64, 0.5 mg/mL pepstatin,
0.5 mg/mL bestatin, 10 mg/mL chymostatin,
and 0.1 ng/mL leupeptin). We then cen-
trifuged the cell lysates at 3,000g for 10 min at
4°C. Protein concentration of supernatant was
measured with Bio-Rad protein assay reagent.
Cellular proteins were separated by 10% SDS-
PAGE and transferred to a polyvinylidene
difluoride membrane. The blot was blocked
with 5% milk in PBS with 0.05% Tween-20
for 1 hr at room temperature, washed brieﬂy,
and then probed with primary antibodies
against phospho-p38 or phospho-ERK1/2
overnight at 4°C. This was followed by incu-
bation with HRP-conjugated secondary anti-
bodies. We detected bands using ECL and
ﬁlms. We then stripped the blot and reprobed
with antibodies against total p38 or total
ERK1/2 and appropriate HRP-conjugated
secondary antibodies.
Statistical analysis. Data are reported as
mean ± SE. Data from the artery ring experi-
ments were analyzed by the repeat-measures
analysis of variance (ANOVA). Data from the
cell experiments were analyzed by ANOVA
followed by the Scheffe’s test for post hoc
comparisons. The statistical analysis was per-
formed using commercially available software
(Statview, version 5.0.1; SAS Institute Inc.,
Cary, NC). We considered a p-value < 0.05 as
statistically signiﬁcant.
Results
Effects of losartan on UP-induced pulmonary
artery constriction. Treatment of isolated rat
pulmonary artery rings with UPs produced a
dose-dependent increase in vasoconstriction
(Figure 1A). At 100 µg/mL, the ring tension
was approximately 25% of that produced by
1 µM phenylephrine. UP-induced pulmonary
vasoconstriction was inhibited by losartan
(0.2 µM), an AT1R receptor antagonist
(Figure 1B).
Effects of UPs on ERK1/2 and p38 phos-
phorylation. Figure 2A shows the time-
dependent increase in phospho-ERK1/2
induced by UPs. The intensity of phosphory-
lated ERK1/2 peaked at 5 min and gradually
decreased. The phosphorylation of ERK1/2 was
enhanced signiﬁcantly by 1–100 µg/mL UPs
(Figure 2B). The phosphorylated p38 increased
with time after UP treatment (Figure 2C).
There was also a dose-dependent increase in the
intensity of phospho-p38 (Figure 2D). The
UP-induced phosphorylation of ERK1/2 and
p38 was completely inhibited by PD98059, an
ERK1/2 MAPK inhibitor, and SB203580, a
p38 MAPK inhibitor (Figure 3A,B). The
UP-induced constriction of rat pulmonary
artery was also attenuated by PD98059 and
SB203580 (Figure 3C,D), indicating that acti-
vation of ERK1/2 and p38 may mediate UP-
induced pulmonary vasoconstriction.
Effects of losartan on UP-induced ERK1/2
and p38 phosphorylation. We then investi-
gated the role of losartan in UP-induced
ERK1/2 and p38 phosphorylation. HPAECs
were pretreated with losartan (0.2 µM) for
30 min before incubation with 10 µg/mL UPs
for 10 min. Figure 4 shows that the UP-
induced ERK1/2 and p38 phosphorylation
was completely inhibited by losartan, indicat-
ing that AT1R mediates the activation of
ERK1/2 and p38 MAPK induced by UPs.
Effects of particle components on ERK1/2
and p38 phosphorylation. Because the soluble
fraction of the particles may better penetrate
the alveolar–capillary membrane and be in
contact with the pulmonary vessels than the
whole particles when inhaled, we determined
whether the soluble fraction of UPs could
activate ERK1/2 and p38 MAPK. The water-
soluble fraction of UPs was capable of
Particles and angiotensin
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Figure 4. Effects of losartan on UP-induced phos-
phorylation of p38 and ERK shown by a representa-
tive Western blot (A) and the densitometry results
(B). Quiescent cells were pretreated with losartan
(0.2 µM) for 30 min and then incubated with 10 µg/mL
UPs for 10 min. Phosphorylation of p38 (p-p38) and
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*p < 0.05 compared with the control. #p < 0.05 compared with Sol-UP.increasing the phosphorylation of ERK1/2
and p38 (Figure 5A,B). The insoluble fraction
was equally effective. Similar to the whole UP,
the soluble-fraction–induced activation of
ERK1/2 and p38 was inhibited by losartan
(Figure 5C,D).
Effects of UP-associated soluble metals on
pulmonary artery constriction. To determine
which water-soluble metal components of
UPs may be responsible for the activation of
ERK1/2 and p38 MAPK, we tested the vaso-
constrictor effects of soluble metals contained
in UPs. We found that Cu and V induced
signiﬁcant vasoconstriction (Figure 6). Other
metals, including Ni, Fe, Mn, Zn, and Al,
produced no or weak vasoconstriction (data
not shown).
Effect of Cu and V on ERK1/2 and p38
phosphorylation. Because only Cu and V
showed signiﬁcant vasoconstrictor activity, we
determined whether or not Cu and V could
activate ERK1/2 and p38 MAPK. Figure 7
shows that CuSO4 and VOSO4 increased
phosphorylation of ERK1/2 and p38 in a
dose-dependent manner.
Effects of losartan on Cu- and V-induced
phosphorylation of ERK1/2 and p38. We fur-
ther determined whether or not the Cu- and
V-induced activation of ERK1/2 and p38 was
inhibitable by losartan. Figure 8 shows that
Cu- and V-induced phosphorylation of p38
was inhibited by losartan. The phosphoryla-
tion of ERK1/2, however, was not inhibited
by losartan (data not shown).
Effects of captopril on UP-induced
ERK1/2 and p38 phosphorylation. Because
angiotensin II, the ligand for AT1R, is a meta-
bolic product of angiotensin-converting
enzyme (ACE), we further determined
whether or not UP-induced AT1R-mediated
MAPK activation required ACE. We pre-
treated the cells with captopril (100 µM), an
ACE inhibitor, for 30 min before the addi-
tion of UPs. Figure 9 shows that the UP-
induced ERK1/2 and p38 phosphorylation
was inhibited by captopril.
Discussion
In this study, we have shown that UPs induced
vasoconstriction in rat pulmonary arterial
rings. Thus, UPs have joined a list of pollutant
particles that have been shown to cause vaso-
constriction, including CAPs (Batalha et al.
2002), residual oil ﬂy ash (Huang et al. 2002),
and diesel particles (Tzeng et al. 2003). We
further have shown that the UP-induced pul-
monary vasoconstriction could be inhibited by
losartan, an AT1R antagonist, indicating that
the renin–angiotensin system may play an
important role. PM has been shown to activate
several vasoactive pathways, including the
release of endothelins (Bouthillier et al. 1998;
Thomson et al. 2004), the activation of EGFR
(Huang et al. 2002), and the inhibition of NO
production (Bai et al. 2001; Bouthillier et al.
1998; Huang et al. 2002; Ikeda et al. 1995).
Compared with these vasoactive pathways, the
angiotensin II–AT1R pathway has the follow-
ing advantages: a) the activation of AT1R-
mediated signaling by particles occurs earlier
than that of endothelins; b) angiotensin II is a
much more potent vasoconstrictor than EGF;
and c) activation of AT1R leads to vasocon-
striction rather than the loss of vasodilator
activity as a result of inhibition of NO produc-
tion. In these aspects, the AT1R pathway may
be a more clinically relevant mechanism for the
acute cardiovascular events associated with
ambient PM demonstrated in the epidemio-
logic and clinical studies, especially in patients
with compromised heart function.
Our study also showed that both the
water-soluble and -insoluble fractions of UPs
Li et al.
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Figure 7. Effects of Cu (as CuSO4) and V (as VOSO4) on phosphorylation of ERK (p-ERK1/2; A and C) and p38
(p-p38; B and D). Results are shown as representative Western blots (A and B) and the densitometry
results (C and D). n = 4 independent experiments. 
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and p38 phosphorylation. The effects by the
water-soluble fraction would be more biologi-
cally relevant because components in this frac-
tion are more likely than the whole particles or
the insoluble fraction to gain access to the pul-
monary vessels quickly by diffusion after the
particles are inhaled into the lung. Many com-
ponents are present in the water-soluble frac-
tion of UPs. Among them are transition
metals. In this study, we found that Cu and V
produced strong vasoconstriction and activated
ERK1/2 and p38. Thus, Cu and V may be
among the active components for PM-induced
vasoconstriction. Residual oil ﬂy ash, a pollu-
tant dust containing abundant V, also pro-
duces vasoconstriction and MAPK activation
(Huang et al. 2002; Silbajoris et al. 2000). Cu
and V may reach the vasculature via specialized
membrane transporters (Chasteen et al. 1986;
Eisses and Kaplan 2002). V appeared to be a
stronger inducer for ERK1/2 and p38 phos-
phorylation than did Cu, but its vasoconstric-
tor property was weaker. This indicated that
V, a nonspeciﬁc protein tyrosine phosphatase
inhibitor, may also activate other signaling
proteins that counteract vasoconstriction. Our
results do not exclude other mechanisms that
are metal independent. Diesel particles, which
contain little metal, impair endothelium-
dependent vasorelaxation (Ikeda et al. 1995)
possibly via the production of reactive oxygen
species inactivating NO. Ultrafine particles
(PM with a mass median aerodynamic diame-
ter < 100 nm), which can more effectively
penetrate the distal lung regions, may produce
cardiovascular adverse effects via more intense
lung inﬂammation (Brown et al. 2000; Utell
and Frampton 2000). Previous studies have
also shown that some components of ultraﬁne
particles deposited in the respiratory tract
could enter the circulation exerting their
adverse effects on the cardiovascular system
(Takenaka et al. 2001).
The UP-induced activation of ERK1/2
and p38 could be inhibited by an antagonist
of AT1R, losartan. Similar inhibition by losar-
tan was also seen when activation was induced
by the water-soluble fraction. This is the ﬁrst
demonstration that PM-induced vascular
effects may be mediated by the angiotensin
signaling. AT1R is one of the four G protein-
coupled receptors that mediates intracellular
signaling induced by angiotensin II (Touyz
and Berry 2002). AT1R activation leads to cell
growth, vascular contraction, inflammatory
responses, and salt and water retention (Touyz
and Berry 2002). These effects are regulated
by complex intracellular signaling pathways
including MAPKs, phospholipase C, protein
kinase C, and phospholipase A2. Our results
that inhibitors of ERK1/2 and p38 MAPKs
attenuated UP-induced vasoconstriction sup-
port the established role of these MAPKs in
angiotensin II–induced vasoconstriction
(Ishihata et al. 2002; Massett et al. 2002;
Meloche et al. 2000; Touyz et al. 1999).
Phosphorylation of MAPKs may further acti-
vate downstream MAPK-activated protein
kinase-2 and heat shock protein 27 with or
without phosphorylation of myosin light
chain (Meloche et al. 2000; Roberts 2004).
Occupancy and activation of AT1R also stim-
ulate many intracellular nonreceptor tyrosine
kinases, such as Src, Pyk2, p130Cas, FAK,
and JAK/STAT (Eguchi and Inagami 2000).
In the cardiovascular system, alterations of
these highly regulated pathways underlie the
pathologic processes such as hypertension and
atherosclerosis, conditions that also have been
linked to PM exposure (Ibald-Mulli et al.
2001; Suwa et al. 2002). That losartan only
inhibited p38 activation induced by V and Cu
indicates that other components of PM may
also be involved in PM-induced ERK1/2
MAPK activation.
The mechanisms by which UPs activate
AT1R are unclear. Because the UP-induced
phosphorylation of ERK1/2 and p38 could
be inhibited by captopril, an ACE inhibitor,
the ACE activity appeared required for these
effects. The vascular endothelial cells contain
a large amount of ACE and can synthesize
angiotensins via the local renin–angiotensin
system (Kifor and Dzau 1987). Such a local
renin–angiotensin system is likely the more
important source of angiotensin II in our cul-
tured HPAECs than is the extracellular
angiotensin I contained in the culture
medium. One might also consider whether or
not UPs may act as an AT1R agonist. At least
one nonpeptide agonist of AT1R has been
described: a biphenylimidazole derivative
(L-162313), whose biologic effects could be
inhibited by AT1R antagonist (Perlman et al.
1995). Binding of nonpeptide agonists of
AT1R may lead to conformational modiﬁca-
tions that affect the preferential binding of
agonists or antagonists (Costa-Neto et al.
2002).
Conclusions
The renin–angiotensin system plays an
important role in many types of inﬂammatory
and cardiovascular diseases. Angiotensin II via
AT1R signaling has been shown to promote
cell growth and regulate the expression of
bioactive substances such as vasoconstrictor
hormones, growth factors, cytokines, aldos-
terone, and extracellular matrix components
(Jacoby and Rader 2003; Schiffrin and Touyz
2004). Our in vitro results indicate that the
angiotensin–AT1R signaling pathway may be
important in mediating vascular effects
induced by PM. Further studies are needed to
determine the role of the circulating and local
renin–angiotensin systems in PM-induced
adverse cardiovascular effects.
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